A practical reference on Reference standard: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Plutonium was first synthesized in 1940 and isolated in 1941 by chemists at the University of California, Berkeley. The Manhattan Project began shortly after the discovery, with most early research (pre-1944) carried out using small samples manufactured using the large cyclotrons at the Berkeley Rad Lab and Washington University in St. Louis. Much of the difficulty encountered during the Manhattan Project regarded the production and testing of nuclear fuel. Both uranium and plutonium were eventually determined to be fissile, but in each case they had to be purified to select for the isotopes suitable for an atomic bomb. With World War II underway, the research teams were pressed for time. Micrograms of plutonium were made by cyclotrons in 1942 and 1943. In late 1943 Robert Oppenheimer is quoted as saying "there's only a twentieth of a milligram in existence." By his request, the Rad Lab at Berkeley made available 1.2 mg of plutonium by the end of October 1943, most of which was taken to Los Alamos for theoretical work there. The world's second reactor, the X-10 Graphite Reactor built at a secret site at Oak Ridge, would be fully operational in 1944. In November 1943, shortly after its initial start-up, it produced a minuscule 500 mg. However, this plutonium was mixed with large amounts of uranium fuel and destined for the nearby chemical processing pilot plant for isotopic separation (enrichment). Gram amounts of plutonium would not be available until early 1944.
In 2005, the US began imposing sanctions targeting Iran's nuclear program, and in 2006 the United Nations Security Council (UNSC) imposed a series of sanctions against Iran. The US and Israel conducted a campaign of cyberwarfare against Iranian nuclear facilities to disrupt their operations, while Israel assassinated several top Iranian nuclear scientists. The UNSC concerns about Iran's nuclear program from 2006 led to the multilateral Joint Comprehensive Plan of Action (JCPOA) between Iran and the P5+1 and the EU in 2015. In January 2020, US president Donald Trump ordered the assassination of Qasem Soleimani, the commander of the Iranian Quds Force. Following the October 7 attacks on Israel and the start of the Gaza war, tensions further escalated with Israel fighting Iran-backed militias across the Middle East, including Hamas, Hezbollah, and the Houthis. Israeli strikes on the Iranian consulate in Damascus and the assassinations of Ismail Haniyeh and Hassan Nasrallah in 2024 were met with Iranian strikes on Israel in April and October. In June 2025, Israel launched the Twelve-Day War by attacking Iranian military and nuclear facilities, provoking Iranian counter-strikes. The United States also joined in support by striking Iranian nuclear facilities during the Twelve-Day War, which ended in a ceasefire. In early 2026, Israeli prime minister Benjamin Netanyahu lobbied President Donald Trump for a joint military strike on Iran, specifically targeting its leadership.
Charles R. Drew Middle School in the Los Angeles Unified School District Charles R. Drew Middle School in Talladega County Schools Charles R. Drew Transition Center in Detroit Public Schools Community District Dr. Charles R. Drew Science in Buffalo Public Schools Charles R. Drew K-8 Center in Miami-Dade County Public Schools Charles Drew Elementary Magnet in Broward County Public Schools Bluford Drew Jemison S.T.E.M Academy in Baltimore Bluford Drew Jemison STEM Academy West in Baltimore City Public Schools Dr. Charles R. Drew Elementary School in Montgomery County Public Schools Charles Drew Elementary School in Washington, D.C. Dr. Charles R. Drew Elementary in Arlington Public Schools Dr. Charles Drew Elementary School in New Orleans Charles R. Drew Charter School in Atlanta Dr. Charles Drew Academy in Ecorse, Michigan Drew Academy in Aldine Independent School District Charles R. Drew Elementary School in Crosby Independent School District Dr. Charles R. Drew College Preparatory Academy in San Francisco Unified School District Charles R Drew ELC 1 in The Bronx
P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) that belongs to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors. This P2Y receptor family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. The P2Y12 receptor is involved in platelet aggregation and is thus a biological target for the treatment of thromboembolisms and other clotting disorders. Two transcript variants encoding the same isoform have been identified for this gene. In the field of purinergic signaling, the P2Y12 protein on the periphery is found mainly but not exclusively on the surface of blood platelets, and is an important regulator in blood clotting. In the central nervous system, this receptor has been found expressed exclusively on microglia, where it is necessary for physiological and pathological microglial actions, such as monitoring neuronal functions and microglial neuroprotection.
Sources: en.wikipedia.org
Though mushroom fruiting bodies are short-lived, the underlying mycelium can itself be long-lived and massive. A colony of Armillaria solidipes (formerly known as Armillaria ostoyae) in Malheur National Forest in the United States is estimated to be 2,400 years old, possibly older, and spans an estimated 2,200 acres (8.9 km2). Most of the fungus is underground and in decaying wood or dying tree roots in the form of white mycelia combined with black shoelace-like rhizomorphs that bridge colonized separated woody substrates.
Another phenotype, Muscle-eye-brain disease (MEB) is the dystroglycanopathy most prevalent in Finland, and is caused by mutations in the POMGnT1, FKRP, FKTN, ISPD, and TMEM5 genes. The POMGnT1 gene is expressed in the same tissues as FKTN, and MEB appears to have a similar severity as FCMD. However, symptoms unique to MEB include glaucoma, atrophy of the optic nerves, and retinal generation. The least severe phenotype of dystroglycanopathies is CMD type 1c (MDC1C), caused by mutations in the FKRP and the LARGE gene, with a phenotype similar to MEB and WWS. MDC1C also includes Limb-Girdle muscular dystrophy.
=== Pulmonary involvement === The lungs are commonly affected in MCTD, with around 75% of patients having lung involvement. The most prevalent pulmonary complications of MCTD are interstitial lung disease (ILD) and pulmonary hypertension; however, a wide spectrum of other pulmonary problems have been recorded, including pleural effusions, pleuritic discomfort, alveolar hemorrhage, and thromboembolic illness. Early indications of pulmonary involvement include dyspnea, dry cough, and pleuritic chest pain.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.